Background and Methods: Randomized, controlled clinical trials (RCTs) have shown a reduced target vessel revascularization (TLR) and a good safety profile for the drug-eluting coronary stent (DES). To evaluate whether the results of RCTs can be generalized to routine clinical practice, all patients receiving at least one DES at two hospitals were entered into a prospective registry. Results: Between March 2003 and March 2004, 477 patients with 601 lesions were treated with CypherTM sirolimus- or TaxusTM paclitaxel-eluting stent. Diabetes was present in 167 (35.3%) patients and 349 (72.8%) had multi-vessel disease. Indication for revascularization was stable angina in 236 (49%), unstable angina in 162 (34.3%) and acute myocardial infarction in 79 (16.7%). Of these, 408 (67.9%) lesions were complex (ACC/AHA classification B2 or higher), 35 (5.9%) were chronic total occlusions, 146 (24.3%) were bifurcating and 77 (12.8%) were in-stent restenosis. Mean target vessel reference diameter was 2.94짹0.35mm and mean lesion length was 26.43짹30.46mm. The majority of lesions were treated with one DES, but 173 (28.8%) lesions were treated with multiple overlapping DES. Overall, 1.33 stents per lesion were implanted and the total length of DES used per lesion was 31.6mm. One hundred and sixty (26.6%) of these lesions had stented segment > 36mm. During clinical follow up, subacute stent thrombosis was documented in 2 (0.4%) patients and the cumulative rate of major adverse cardiac events (death, myocardial infarction, or TLR) was 8.3%. At 6 months, the angiographically proven binary in-segment restenosis was documented only in 7.3% of lesions. The complete quantitative coronary angiographic profiles will be available at the time of presentation. Conclusion: The excellent results obtained with DES in RCTs can be replicated in this ���real world��� registry, in which the patient and lesion characters were much more complex than those of RCTs.